You are here

AntiDoSE Microneedle Patch - An Antimicrobial, Dissolvable, and Stabilizing Excipient for Intradermal Delivery of Human Rabies Vaccine

Award Information
Agency: Department of Health and Human Services
Branch: Centers for Disease Control and Prevention
Contract: 75D30121P11937
Agency Tracking Number: 75D30121P11937
Amount: $243,500.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: 27
Solicitation Number: PHS 2020-1
Timeline
Solicitation Year: 2020
Award Year: 2021
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
301 1st St SW Suite 200
Roanoke, VA 24011-1921
United States
DUNS: 627132913
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Lindsay Woodard
 (434) 220-1559
 woodard@lunainc.com
Business Contact
 Mary Hudson
Phone: (434) 220-1559
Email: submissions307@lunainc.com
Research Institution
N/A
Abstract

ABSTRACT: Approximately 60,000 human deaths occur each year from rabies. Although rabies vaccines have been developed for pre- and post-exposure prophylaxis (PEP), remote communities are disproportionally susceptible to the life-threatening infection. In these communities, access to the requisite healthcare facilities is limited, and there are high costs and complex regimens associated with the treatment. Further, current vaccines require maintenance of cold chain and bulky packaging. Vaccine delivery administered intradermally using a dissolvable microneedle approach could result in key benefits such as reduced packaging and administrative needs, along with dose sparing cost savings. Challenges remain within the development of disposable microneedles for vaccine delivery, including maintenance of antigen stability without the need for cold chain and device sterilization. Luna proposes to address these limitations through development of the AntiDoSE microneedle patch. The technology builds upon existing work at Luna, and the stabilizing matrix is expected to reduce cold chain requirements while exhibiting antimicrobial behavior and controlled antigen release during dissolution. The proposed Phase I program includes objectives aimed at demonstrating the feasibility of the novel excipient for microneedle delivery of the human rabies vaccine.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government